Welcome to RISE Life Science Corp. (RLSC), a Canadian Securities Exchange listed company.
RISE is pioneering new and innovative products in an emerging category: hemp-based health and wellness. RISE’s portfolio includes products intended to support sleep, general wellness, and sexual and emotional wellbeing. With the broad range of our target consumer audiences, RISE is not just in the niche hemp product business. We’re in the health and wellness business
Our company has a vertically integrated team incorporating superior R&D and manufacturing; marketing strategy and brand building; and dedicated retail sales teams in market.
We bring all expertise under one roof, with no need to engage third-party manufacturers, maintaining control and protecting our margins. Product research and development, formulation, product packaging and fulfillment, and delivery to market – all executed with efficiency.
Interested in RISE?
RISE Life Science Corp. (RLSC), is a Canadian Securities Exchange listed company.
Scroll down for company highlights.
Shares of RISE Life Science Corp. are traded on the Canadian Securities Exchange ticker symbol “RLSC.”
Shares of RISE Life Science Corp. cannot be purchased directly from the company. From time to time the Company has sold shares directly to the public as part of its private placement process. There are investor requirements and certain exemptions which must be met to qualify. For more information about our private placements, please contact firstname.lastname@example.org.
Current share data can be found on the Canadian Securities Exchange under the ticker symbol “RLSC”.
RISE Life Science Corp.’s transfer agent is AST Trust Company (Canada). AST can be contacted at (800) 387-0825 or via their contact page here.
RISE Life Science Corp. does not currently pay a dividend.
As RISE Life Science Corp. does not currently pay a dividend, the company does not offer a DRIP.
If you are a registered stockholder and have questions regarding your holdings or if there are account changes to be made to the account (mailing address, account name, shareholder documentation requests), please contact RISE Life Science Corp.’s transfer agent, AST Trust Company (Canada). AST can be contacted at (800) 387-0825 or via their contact page here. If you own shares through a brokerage account, contact the broker who is responsible for your account.
Please contact our headquarters at email@example.com, or by phone at +1 (855) 477-RISE.
RISE Life Science Corp.’s fiscal year ends November 30. RISE Life Science Corp.’s quarters are Q1 (February 28), Q2 (May 31), Q3 (August 31).
These documents are available at sedar.com.
Insider share ownership information is available on the System for Electronic Disclosure by Insiders (“SEDI”) at sedi.ca.
Our board provides direction and oversight to bring in top investors who understand the power of brands in the new industry footrace.
Executive Chairman & Director
Scott achieved rapid revenue growth as CEO of Pointstreak Sports Technologies from 2009 to 2015, earning awards that included Deloitte’s Technology Fast 50 Winner in 2012 as one of the fifty fastest growing technology companies in Canada and Deloitte’s Technology Fast 500 Winner in 2014 as one of the 500 fastest growing technology companies in North America.
President & Director
Ryan has in-depth experience in cannabis-based product development, manufacturing and distribution earned previously as President and CEO of Cultivate Kind and Managing Partner of Life Bloom Organics. Ryan adds an important knowledge and expertise of the biggest and most sophisticated cannabis market in the world to RISE.
Michael is a veteran of private investment and corporate management, incubating and managing early stage resource, healthcare and technology companies. He has extensive experience in equity and debt financing, M&A and commercial and operational matters. Mike served as General Counsel and Corporate Secretary for Intellipharmaceutics International Inc., a Nasdaq and TSX listed pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release drugs.
Ashwath is the CEO of the ASTOR Group, a private investment and advisory business, working in the fields of Real Estate, Mining, Tech and Biotech. He spent many years in the commodity trading and mining business, owning buying and selling companies over 30 years and has substantial experience in the industry. Ashwath is a director of several companies, both public and private in both executive and non-executive roles. He also devotes significant time to non-profit activities in the fields of healthcare and education.